Illegal tirzepatide injections have prompted a warning from the Philippine Food and Drug Administration (FDA), which is urging consumers to avoid unregistered weight-loss medications being sold through unauthorized channels. The advisory highlights concerns over products whose safety, quality, and effectiveness have not been established through the required regulatory process.

In FDA Advisory No. 2026-1020, the agency identified an unregistered product labeled as Tirzepatide Subcutaneous Use Only, 30 mg Multi-Use Vial, accompanied by bacteriostatic water. The product had not completed the required registration process and did not have a Certificate of Product Registration (CPR), meaning its quality, safety, and effectiveness could not be guaranteed.

The warning comes amid increasing concerns about unauthorized weight-loss medications being sold through social media and other informal channels.

The National Bureau of Investigation (NBI) previously conducted an operation against suspected illegal tirzepatide sellers in Tondo, Manila. In a May 15, 2026, announcement, the bureau reported the arrest of two individuals following an investigation into the online sale of the unregistered medication. Authorities also seized products reportedly worth ₱310,000.

Medical professionals have warned that unregistered injectable medicines may expose consumers to serious risks, including incorrect dosages, contamination, inconsistent drug concentrations, and unknown ingredients.

Tirzepatide is a prescription medication used for managing type 2 diabetes and, in approved formulations and indications, chronic weight management. However, consumers should understand that not every product marketed under its name is legitimate or authorized for sale.

The FDA advises the public to verify medicine registrations through its official verification portal and purchase prescription medications only from legitimate sources.

Consumers are also encouraged to consult licensed healthcare professionals before using weight-loss injections.

The agency’s warning highlights the importance of prioritizing safety over quick weight-loss solutions, particularly as demand for injectable weight-management treatments continues to grow.